Filing Flows

Filing Flows › Denali Therapeutics (DNLI) › Next earnings date

Denali Therapeutics (DNLI) earnings: missed the estimate

Denali Therapeutics (DNLI) reported on Nov 3, 2026 and missed the EPS estimate: −$0.66 against −$0.37 (-79.3%). Revenue was $17.8M for Q3 2026. It beat the EPS estimate in 60% of the quarters on record.

Last result−79.3% vs estimate
Beat rate60%

The last report

Denali Therapeutics reported revenue of $17.8M for the third quarter 2026, net earnings $70.1M. How it makes money → · Every quarter →

Denali Therapeutics: EPS against the estimate, last 5 reportsDenali Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.76−$0.74Nov 25−$0.75−$0.73Feb 26−$0.71−$0.69May 26−$0.47−$0.68Aug 26−$0.37−$0.66Nov 26
Latest (Nov 26): Estimate −$0.37, Reported −$0.66.

Denali Therapeutics' latest quarter

Denali Therapeutics, Q3 2026: revenue $17.8M, operating margin -713.0%, net earnings $70.1M, operating cash flow −$117M. The chart follows the revenue to costs, profit and cash.

Questions

Did Denali Therapeutics beat earnings?

Denali Therapeutics (DNLI) reported on Nov 3, 2026 and missed the EPS estimate: −$0.66 against −$0.37 (-79.3%).

When does DNLI report earnings?

The next date is not set yet.

Does Denali Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.